(Q37765048)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

The present and the future landscape of treatment of advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Armando Santoro

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Lorenza Rimassa

series ordinal

1

1 reference

22 August 2017

Armando Santoro

series ordinal

2

1 reference

22 August 2017

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

Digestive and Liver Disease

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

42 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

S273-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960516-6

7 January 2021

10.1016/S1590-8658(10)60516-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20547314%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference